Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation

NICE technology appraisals [TA311] Published date:

Bortezomib (given with a drug called dexamethasone, or with dexamethasone and thalidomide) is recommended as a possible treatment for adults with multiple myeloma before having chemotherapy and stem cell transplantation, if their multiple myeloma has not been treated before.

What does this mean for me?

If you have multiple myeloma as described above, and your doctor thinks that bortezomib is the right treatment, you should be able to have the treatment on the NHS.

Bortezomib should be available on the NHS within 3 months of the guidance being issued.

Get involved